por John R. Fischer
, Senior Reporter | November 20, 2020
GE Healthcare has acquired Prismatic Sensors AB.
The two plan to develop a clinical photon counting CT (PCCT) system in the near future using Prismatic Sensors AB's Deep Silicon detector technology.
“Silicon-based detectors will enable superior spectral resolution without compromising on count rate or spatial resolution,” said Mats Danielsson, CEO of Prismatic Sensors, in a statement.
PCCT enables clinicians to view minute details of organ structures, improves tissue characterization, provides more accurate material density measurement (or quantification) and lowers radiation dose for adult and pediatric patients. Prismatic Sensors’ silicon sensors can be positioned in a way that makes PCCT detectors deep enough to absorb very high-energy photons and fast enough to count hundreds of millions of CT photons per second.
Quest Imaging Solutions provides all major brands of surgical c-arms (new and refurbished) and carries a large inventory for purchase or rent. With over 20 years in the medical equipment business we can help you fulfill your equipment needs
GE began studying PCCT in 1993. It released the first PCCT prototype in the world in 2006 using cadmium-based detectors. Cadmium-based detectors, however, are limited as X-ray detector materials due to their imperfect crystal structure and contamination. Silicon, in contrast, is the purest material produced for use in detectors.
The technology shows potential in oncology, cardiology, neurology, as well as for low-dose acquisitions and for applications that benefit from tissue specificity. It offers higher spatial resolution and contrast that help with imaging small blood vessels and vascular pathologies, and monitoring changes in cancer at an earlier stage.
“From the first X-ray machines to the first photon-counting CT prototype, GE Healthcare is committed to pioneering next generation technologies to achieve precision health and improve lives. We are excited about this cutting-edge approach with Deep Silicon and its clinical potential,” said Kieran Murphy, president and CEO of GE Healthcare.
The acquisition is expected to be completed by January 2021.
Financial details and terms of the transaction were not disclosed.